• 1
    Castleberry RP. Biology and treatment of neuroblastoma. Pediatr Clin North Am. 1997; 44: 919937.
  • 2
    Matthay KK. Neuroblastoma: biology and therapy. Oncology. 1997; 11: 18571866.
  • 3
    Evans AE, Silber JH, Shpilsky A, et al. Successful management of low-stage neuroblastoma without adjuvant therapies: a comparison of two decades, 1972 through 1981 and 1982 through 1992, in a single institution. J Clin Oncol. 1996; 14: 24052410.
  • 4
    Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med. 1999; 341: 11651173.
  • 5
    Finklestein JZ, Klemperer MR, Evans A, et al. Multiagent chemotherapy for children with metastatic neuroblastoma: a report from the Childrens Cancer Study Group. Med Pediatr Oncol. 1979; 6: 179188.
  • 6
    Blatt J, Gula MJ, Orlando SJ, et al. Indolent course of advanced neuroblastoma in children older than 6 years at diagnosis. Cancer. 1995; 76: 890894.
  • 7
    Franks LM, Bollen A, Seeger RC, et al. Neuroblastoma in adults and adolescents. An indolent course with poor survival. Cancer. 1997; 79: 20282035.
  • 8
    Silber JH, Evans AE, Fridman M. Models to predict outcome from childhood neuroblastoma: the role of serum ferritin and tumor histology. Cancer Res. 1991; 51: 14261433.
  • 9
    Shuster JJ, McWilliams NB, Castleberry R, et al. Serum lactate dehydrogenase in childhood neuroblastoma. Am J Clin Oncol. 1992; 15: 295303.
  • 10
    Vogel JM, Coddon DR, Simon N, Gitlow SE. Osseous metastases in neuroblastoma. A 17-year survival. Cancer. 1970; 26: 13541360.
  • 11
    Jaffe N. Recrudescence of neuroblastoma after apparent cure. J Natl Cancer Inst. 1976; 57: 731732.
  • 12
    Cervera A, Kingston JE, Malpas JS. Late recurrence of neuroblastoma: a report of five cases and review of the literature. Pediatr Hematol Oncol. 1990; 7: 311322.
  • 13
    Pierce ST. Long-term survival in refractory recurrent neuroblastoma. J Pediatr Hematol Oncol. 1996; 18: 202205.
  • 14
    Cotterill SJ, Pearson ADJ, Pritchard J, et al. Late relapse and prognosis for neuroblastoma patients surviving 5 years or more: a report from the European Neuroblastoma Study Group “Survey.” Med Pediatr Oncol. 2001; 36: 235238.
  • 15
    Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993; 11: 14661477.
  • 16
    Rosen EM, Cassady JR, Frantz CN, et al. Stage IV-N: a favorable subset of children with metastatic neuroblastoma. Med Pediatr Oncol. 1985; 13: 194198.
  • 17
    Green AA, Hayes FA, Hustu HO. Sequential cyclophosphamide and doxorubicin for induction of complete remission in children with disseminated neuroblastoma. Cancer. 1981; 48: 23102317.
  • 18
    Creemers GJ, Gerrits CJH, Eckardt JR, et al. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. J Clin Oncol. 1997; 15: 10871093.
  • 19
    Capelli C, Hartmann O, Pein F, et al. Efficacy of palliative oral etoposide in metastatic neuroblastoma relapsing after high-dose chemotherapy [abstract]. Med Pediatr Oncol. 1995; 25: 319.
  • 20
    Kushner BH, Kramer K, Cheung N-KV. Oral etoposide for refractory and relapsed neuroblastoma. J Clin Oncol. 1999; 17: 32213225.
  • 21
    Frantz CN, Gelber RD, Belli JA, et al. Aggressive treatment of neuroblastoma. In: RaybaudC, editor. Pediatric oncology. Amsterdam: Excerpta Medica, 1982: 175179.
  • 22
    Miser JS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol. 1987; 5: 11911198.
  • 23
    Kushner BH, Helson L. Coordinated use of sequentially escalated cyclophosphamide and cell-cycle-specific chemotherapy (N4SE protocol) for advanced neuroblastoma: experience with 100 patients. J Clin Oncol. 1987; 5: 17461751.
  • 24
    Cairo MS, Krailo M, Miser J, et al. Excellent results of the use of ifosfamide, carboplatin, etoposide (I.C.E.) in children with recurrent or refractory solid tumors[abstract]. Proc Am Soc Clin Oncol. 1996; 15: 468.
  • 25
    Saylors RL, Stewart CF, Zamboni WC, et al. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group study. J Clin Oncol. 1998; 16: 945952.
  • 26
    Nitschke R, Parkhurst J, Sullivan J, et al. Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol. 1998; 20: 315318.
  • 27
    Kushner BH, O'Reilly RJ, LaQuaglia M, et al. Dose-intensive use of cyclophosphamide in ablation of neuroblastoma. Cancer. 1990; 66: 10951100.
  • 28
    Campbell LA, Seeger RC, Harris RE, et al. Escalating doses of continuous infusion combination chemotherapy for refractory neuroblastoma. J Clin Oncol. 1993; 11: 623629.
  • 29
    Kushner BH, LaQuaglia MP, Bonilla MA, et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol. 1994; 12: 26072613.
  • 30
    Alvarado CS, Kretschmar C, Joshi VV, et al. Chemotherapy for patients with recurrent or refractory neuroblastoma: a POG phase II study. J Pediatr Hematol Oncol. 1997; 19: 6267.
  • 31
    Cheung N-KV, Kushner BH, LaQuaglia M, et al. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Med Pediatr Oncol. 2001; 36: 224230.
  • 32
    Kushner BH, Kramer K, Meyers PA, et al. Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors. Med Pediatr Oncol. 2000; 35: 468474.
  • 33
    Cheung N-KV, Kushner BH, Cheung I, et al. Anti-GD2 antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol. 1998; 16: 30533060.
  • 34
    Kushner BH, Kramer K, Cheung N-KV. Phase II trial of the anti-GD2 monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol. 2001; 19: 41894194.
  • 35
    Kushner BH, Wolden S, LaQuaglia MP, et al. Hyperfractionated low-dose radiotherapy (21 Gy) for high-risk neuroblastoma after intensive chemotherapy and surgery. J Clin Oncol. 2001; 19: 28212828.
  • 36
    Mora J, Cheung N-KV, Chen L, Qin J, Gerald W. Loss of heterozygosity at 19q13.3 is associated with locally aggressive neuroblastoma. Clin Cancer Res. 2001; 7: 13581361.
  • 37
    Kinnier Wilson LM, Draper GJ. Neuroblastoma, its natural history and prognosis: a study of 487 cases. Br Med J. 1974; 3s: 301307.
  • 38
    Jaffe N. Neuroblastoma: review of the literature and an examination of factors contributing to its enigmatic character. Cancer Treat Rev. 1976; 3: 6182.
  • 39
    Bowman LC, Hancock ML, Santana VM, et al. Impact of intensified therapy on clinical outcome in infants and children with neuroblastoma: The St. Jude Children's Research Hospital experience, 1962-1988. J Clin Oncol. 1991; 9: 15991608.
  • 40
    Cotterill SJ, Pearson ADJ, Pritchard J, et al. Clinical prognostic factors in 1277 patients with neuroblastoma: results of the European Neuroblastoma Study Group “survey.” Eur J Cancer. 2000; 36: 901908.
  • 41
    Ladenstein R, Lasser C, Hartmann O, et al. Impact of megatherapy on survival after relapse from stage 4 neuroblastoma in patients over 1 year of age at diagnosis: a report from the European Group for Bone Marrow Transplantation. J Clin Oncol. 1993; 11: 23302341.
  • 42
    Bagniewski PG, Reid JM, Villablanca JG, et al. A phase I pharmacokinetic study of fenretinide (HPR) in children with high-risk solid tumors. A Childrens Cancer Group (CCG) study [abstract]. Proc Am Assoc Cancer Res. 1999; 40: 92.
  • 43
    Yu AL, Uttenreuther-Fischer MM, Huang C-S, et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol. 1998; 16: 21692180.
  • 44
    Bowman L, Grossman M, Rill D, et al. IL-2 adenovirus-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood. 1998; 92: 19411949.
  • 45
    Yu AL, Eskenazi A, Strother D, Castleberry R. A pilot study of anti-idiotype monoclonal antibody as tumor vaccine in patients with high-risk neuroblastoma [abstract]. Proc Am Soc Clin Oncol. 2001; 20: 368a.
  • 46
    Geiger JD, Hutchinson RJ, Hohenkirk LF, et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res. 2001; 61: 85138519.
  • 47
    Matthay KK, DeSantes K, Hasegawa B, et al. Phase I dose escalation of 131I-metaiodobenzyl-guanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol. 1998; 16: 229236.
  • 48
    Frappaz D, Michon J, Coze C, et al. LMCE3 treatment strategy: results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis. J Clin Oncol. 2000; 18: 468476.
  • 49
    LaQuaglia MP, Kushner BH, Heller G, et al. Stage 4 neuroblastoma diagnosed at more than 1 year of age: gross total resection and clinical outcome. J Pediatr Surg. 1994; 29: 11621166.
  • 50
    Hayes FA, Green AA. Second complete remissions (CR) in children with metastatic neuroblastoma (NB) [abstract]. Proc Am Soc Clin Oncol. 1985; 4: C-921.
  • 51
    Berthold F, Hero B, Breu H, et al. The recurrence patterns of stages I, II, and III neuroblastoma: experience with 77 relapsing patients. Ann Oncol. 1996; 7: 183187.
  • 52
    Rubie H, Hartmann O, Michon J, et al. N-myc amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 Study. J Clin Oncol. 1997; 15: 11711182.
  • 53
    Hanada M, Krajewski S, Tanaka S, et al. Regulation of Bcl-2 oncoprotein levels with differentiation of human neuroblastoma cells. Cancer Res. 1993; 53: 49784986.
  • 54
    Cheung N-KV, Kushner BH, Kramer K. Monoclonal antibody-based therapy of neuroblastoma. Hematol Oncol Clin North Am. 2001; 15: 853866.